Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.59 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1195260 | 1.00 | NPSR1 (0.62) | NPSR1MAPTL3MBTL1TP53HTT | |
| SCHEMBL1195279 | 0.84 | NPSR1 (0.65) | NPSR1MAPTL3MBTL1TP53HTT | |
| SCHEMBL1195275 | 0.84 | NPSR1 (0.65) | NPSR1MAPTL3MBTL1TP53HTT | |
| SCHEMBL1195369 | 0.82 | NPSR1 (0.62) | NPSR1MAPTL3MBTL1TP53HTT | |
| SCHEMBL1195316 | 0.82 | NPSR1 (0.62) | NPSR1MAPTL3MBTL1TP53HTT | |
| SCHEMBL28001411 | 0.80 | NPSR1 (0.57) | NPSR1MAPTL3MBTL1TP53HTT | |
| SCHEMBL28001057 | 0.80 | NPSR1 (0.57) | NPSR1MAPTL3MBTL1TP53HTT | |
| SCHEMBL1195476 | 0.79 | ALDH1A1 (0.61) | MAPTHTTKMT2AMEN1 | |
| SCHEMBL10485687 | 0.79 | ANO1 (0.56) | NPSR1MAPTL3MBTL1TP53HTT | |
| SCHEMBL1195477 | 0.79 | ALDH1A1 (0.61) | MAPTHTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028562-A1 | DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE | UNIWERSYTET JAGIELLONSKI (PL) | 2011-02-03 | — | — | US | claimed |
| US-8841347-B2 | Derivatives of aminoalkanols, method of obtaining of aminoalkanols and their use | UNIWERSYTET JAGIELLONSKI (PL) | 2014-09-23 | — | — | US | disclosed |
| US-8633251-B2 | Derivatives of aminoalkanols, method of obtaining of aminoalkanols and their use | UNIWERSYTET JAGIELLONSKI (PL) | 2014-01-21 | — | — | US | disclosed |
| US-20130289118-A1 | DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE | UNIWERSYTET JAGIELLONSKI (PL) | 2013-10-31 | — | — | US | disclosed |
| US-20110028562-A1 | DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE | UNIWERSYTET JAGIELLONSKI (PL) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289118-A1 | DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE | SCN1A, SCN3A, ACHE | NPSR1 611/4885MAPT 1048/4885L3MBTL1 3706/4885 |
| US-20110028562-A1 | DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE | ACHE, CNR2, SCN1A | NPSR1 687/4885MAPT 1073/4885L3MBTL1 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.